September 22, 2016
1 min read
Save

Resistin, visfatin were associated with clinical severity of knee OA in women

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In women with knee osteoarthritis and join effusion, resistin was associated with clinical severity while visfatin was inversely associated with severity, according to recently published findings.

Investigators previously determined adipokines, such as resistin and visfatin, were related to knee osteoarthritis (OA), the researchers wrote. However, the exact role of these adipokines has not been determined.

The researchers performed a cross-sectional study of 115 women with symptomatic primary knee OA and ultrasound-confirmed joint effusion. They assessed radiographic severity according to the Kellgren-Lawrence scale and determined clinical severity according to the Lequesne index. They also assessed age, physical exercise and knee OA symptom duration, as well as other cardiovascular risk factors and anthropomorphic measurements. Using an enzyme-linked immunosorbent assay in synovial fluid, they measured the following adipokines: leptin; adiponectin; resistin; visfatin; osteopontin; omentin; and chemerin. They also measured the inflammatory markers tumor necrosis factor alpha, interleukin-6 and high-sensitivity C-reactive protein.

They found Kellgren-Lawrence index, physical exercise, all anthropomorphic measurements and tumor necrosis factor alpha, as well as high levels of leptin, resistin and ostepontin were associated with knee OA severity. After investigators adjusted their findings for cofounders, visfatin was inversely associated with clinical severity while resistin and radiological parameters, physical exercise and waist circumference were directly associated with OA severity. – by Will Offit

Disclosure: The researchers report no relevant financial disclosures.